Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID‐19 Spanish inpatients
Crisanto Díez, Maria Iglesias‐González, Maria Giralt‐López, et al.
Acta Psychiatrica Scandinavica (2021) Vol. 143, Iss. 6, pp. 526-534
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Tomiko Oskotsky, Ivana Marić, Alice Tang, et al.
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2133090-e2133090
Open Access | Times Cited: 127
Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action
Lin Liu, Shuyu Ni, Wei Yan, et al.
EClinicalMedicine (2021) Vol. 40, pp. 101111-101111
Open Access | Times Cited: 112
COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review
Marc D. Binder, Victor Mazereel, Marc Stroobants, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 57
Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort
Catherine L. Clelland, Krista Ramiah, Louisa J. Steinberg, et al.
BJPsych Open (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 42
Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study
Nicolas Hoertel, Marina Sánchez‐Rico, Erich Gulbins, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 31
Hospital length of stay for COVID-19 patients: A systematic review and meta-analysis
Yousef Alimohamadi, Elahe Mansouri Yekta, Mojtaba Sepandi, et al.
Multidisciplinary Respiratory Medicine (2022) Vol. 17
Open Access | Times Cited: 31
COVID-19 risk, course and outcome in people with mental disorders: a systematic review and meta-analyses
Patricio Molero, Gabriel Reina, Jan Dirk Blom, et al.
Epidemiology and Psychiatric Sciences (2023) Vol. 32
Open Access | Times Cited: 20
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis
Hosein Nakhaee, Moein Zangiabadian, R. Bayati, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0267423-e0267423
Open Access | Times Cited: 26
COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review
Udo Bonnet, Georg Juckel
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 3, pp. 284-292
Open Access | Times Cited: 22
Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection
Shaymaa Elsayed Khater, Ahmed El‐Khouly, Hend Mohamed Abdel‐Bar, et al.
International Journal of Pharmaceutics (2021) Vol. 607, pp. 121023-121023
Open Access | Times Cited: 28
Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France
Nicolas Hoertel, Marina Sánchez‐Rico, Pedro de la Muela, et al.
Biological Psychiatry Global Open Science (2022) Vol. 3, Iss. 1, pp. 56-67
Open Access | Times Cited: 19
Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis
Giovanna Fico, Ulker Isayeva, Michele De Prisco, et al.
European Neuropsychopharmacology (2022) Vol. 66, pp. 30-44
Open Access | Times Cited: 19
The impact of preexisting psychiatric disorders and antidepressant use on COVID-19 related outcomes: a multicenter study
Katharina Schultebraucks, Wivine Blekić, Cale Basaraba, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 6, pp. 2462-2468
Open Access | Times Cited: 11
Psychosis and substance abuse increase the COVID-19 mortality risk
Ana Catalán, Clàudia Aymerich, Amaia Bilbao, et al.
Psychological Medicine (2022) Vol. 53, Iss. 9, pp. 4236-4244
Open Access | Times Cited: 17
Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis
Steven H. Rauchman, Sherri Mendelson, Courtney Rauchman, et al.
Journal of Clinical Medicine (2021) Vol. 11, Iss. 1, pp. 70-70
Open Access | Times Cited: 18
The utility of salivary CRP and IL-6 as a non-invasive measurement evaluated in patients with COVID-19 with and without diabetes
Endang Winiati Bachtiar, Boy M. Bachtiar, Ardiana Kusumaningrum, et al.
F1000Research (2024) Vol. 12, pp. 419-419
Open Access | Times Cited: 2
Cross-National Variations in COVID-19 Mortality: The Role of Diet, Obesity and Depression
Ravi Philip Rajkumar
Diseases (2021) Vol. 9, Iss. 2, pp. 36-36
Open Access | Times Cited: 16
Can selective serotonin reuptake inhibitors/serotonin and norepinephrine reuptake inhibitor antidepressants decrease the "cytokine storm" in the course of COVID-19 pneumonia?
Leonardo Fei, Gabriele Santarelli, Giulio D’ANNA, et al.
Panminerva Medica (2021) Vol. 65, Iss. 3
Closed Access | Times Cited: 15
Synthesis and application of ferromagnetic graphene oxide nanocomposite as an effective adsorbent for Clonazepam: Batch experiments, modeling, regeneration, and phytotoxicity
Bruna Figueiredo do Nascimento, Luís F.O. Silva, Caroline Maria Bezerra de Araújo, et al.
Journal of environmental chemical engineering (2022) Vol. 10, Iss. 5, pp. 108331-108331
Closed Access | Times Cited: 9
Association of serum interleukin-6 and C-reactive protein with depressive and adjustment disorders in COVID-19 inpatients
Maria Iglesias‐González, Marc Boigues, David Sanagustín, et al.
Brain Behavior & Immunity - Health (2021) Vol. 19, pp. 100405-100405
Open Access | Times Cited: 12
Psychiatric polygenic risk as a predictor of COVID-19 risk and severity: insight into the genetic overlap between schizophrenia and COVID-19
María Alemany-Navarro, Silvia Diz‐de Almeida, Raquel Cruz, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
A hybrid modeling framework for generalizable and interpretable predictions of ICU mortality across multiple hospitals
Moein E. Samadi, Jorge Guzman-Maldonado, Kateryna Nikulina, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study
Samuel Pintos‐Rodríguez, Irene Visos‐Varela, Almudena Rodríguez-Fernández, et al.
The International Journal of Neuropsychopharmacology (2024) Vol. 27, Iss. 4
Open Access | Times Cited: 1
Investigation of the relationship between anxiety-depression, systemic immune-inflammation index and clinical progression in COVID-19
Begüm Aygen GÜMÜŞ, Ali Emre Şevik, Sevil Alkan
Bratislavské lekárske listy/Bratislava medical journal (2024) Vol. 125, Iss. 10, pp. 589-596
Open Access | Times Cited: 1
Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update
Udo Bonnet, Georg Juckel
Fortschritte der Neurologie · Psychiatrie (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top